Abstract
This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide (CTX) and mitoxantrone (MXT), with dose escalation of paclitaxel. Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time. Bone Marrow Transplantation (2001) 27, 989–998.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Northouse LL . A longitudinal study of the adjustment of patients and husbands to breast cancer Oncol Nurs Forum 1990 17: 39–43
Buccheri G . Depressive reactions to lung cancer are common and often followed by a poor outcome Eur Resp J 1998 11: 173–178
Coates A, Porzsolt F, Osoba D . Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advance malignancy Eur J Cancer 1997 33: 1025–1030
Herndon JE, Fleishman SB, Kornblith AB et al. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 1999 85: 333–340
Feld R . Endpoints in cancer clinical trials: is there a need for measuring quality of life? Supp Care Cancer 1995 3: 23–27
Kiebert GM, Curran D, Aaronson NK . Quality of life as an endpoint in EORTC clinical trials Stat Med 1998 17: 561–569
Schwarz R, Bernhard J, Flechtner H et al. Guidelines for the assessment of quality of life in oncology – implementing adequate methods and their content J Cancer Res Clin Oncol 1994 120: 691–692
Spilker B . Quality of Life Assessment in Clinical Trials Raven Press: New York 1990
Taylor K, Macdonald K, Bezjak A et al. Physicians’ perspective on quality of life: an exploratory study of oncologists Qual Life Res 1996 5: 5–14
Morris J, Perez D, McNoe B . The use of quality of live data in clinical practice Qual Life Res 1998 7: 85–91
Gough I, Dalgleish L . What value is given to quality of life assessment by health professionals considering response to palliative chemotherapy for advanced cancer? Cancer 1991 68: 220–225
Bezjak A, Ng P, Taylor KM et al. A preliminary survey of oncologists perceptions of quality of life information Psycho-oncology 1997 6: 107–113
Ganz PA . Impact of quality of life outcomes on clinical practice Oncology 1995 9: 61–65
Finlay IG, Dunlop R . Quality of life assessment in palliative care Ann Oncol 1994 5: 13–18
Gluck S, Germond C, Lopez P et al. A phase I trial of high-dose paclitaxel, cyclophosphamide and mitroxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer Eur J Cancer 1998 34: 1008–1014
Whedon M, Ferrell BR . Quality of life in adult bone marrow transplant patients: beyond the first year Semin Oncol Nurs 1994 10: 42–57
Winer EP, Sutton LM . Quality of life after bone marrow transplantation Oncology 1994 8: 19–27
Peters WP . Autologous bone marrow transplantation for breast cancer Curr Opin Oncol 1992 4: 278–282
Peters WP, Ross M, Vredenburgh JJ et al. High dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer J Clin Oncol 1993 11: 1132–1143
Winer EP, Hardee M, Brunatti C et al. Quality of life (QL) assessment in patients with breast cancer surviving 12 months or more following high dose chemotherapy with autologous bone marrow transplant Proc Am Soc Clin Oncol 1992 11: 383
Whedon M, Stearns D, Mills LE . Quality of life of long-term adult survivors of autologous bone marrow transplantation Oncol Nurs Forum 1995 22: 1527–1535
Winer EP, Lindley C, Hardee M et al. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support Psycho-Oncology 1999 8: 167–176
Mytko JJ, Knight SJ, Chastain D et al. Coping strategies and psychological distress in cancer patients before autologous bone marrow transplant J Clin Psych Med Sett 1997 3: 355–366
McQuellon RP, Craven B, Russell GB et al. Quality of life in breast cancer patients before and after autologous bone marrow transplantation Bone Marrow Transplant 1996 18: 579–584
Larsen J, Gardulf A, Nordstrom G et al. Health-related quality of life in women with breast cancer undergoing autologous stem-cell transplantation Cancer Nurs 1996 19: 368–375
Vose JM, Kennedy BC, Bierman PJ et al. Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies Cancer 1992 69: 784–789
Chao NJ, Tierney DK, Bloom JR et al. Dynamic assessment of quality of life after autologous bone marrow transplantation Blood 1992 80: 825–830
Amato JJ, Williams M, Greenberg C et al. Psychological support to an autologous bone marrow transplant unit in a community hospital: a pilot experience Psycho-Oncol 1998 7: 121–125
Hjermstad MJ, Evenson SA, Kvaloy SO et al. Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study J Clin Oncol 1999 17: 706–718
Watson M, Wheatley K, Harrison GA et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone Cancer 1999 86: 1231–1239
Hann DM, Garovoy N, Finkelstein B et al. Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: a longitudinal comparative study J Pain Sympt Management 1999 17: 311–319
Schipper H, Clinch J, McMurray A, Levitt M . Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation J Clin Oncol 1984 2: 472–483
Lindley CM, Hirsch JD, O'Neill CV . Quality of life consequences of chemotherapy-induced emesis Qual Life Res 1992 1: 331–340
Hjermstad MJ, Holte H, Evensen SA et al. Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant 1999 24: 911–918
Pasacreta JV, Pickett M . Psychosocial aspects of palliative care Semin Oncol Nurs 1998 14: 110–120
Zabora JR, Blanchard CG, Smith ED et al. Prevalence of psychological distress among cancer patients across the disease continuum J Psych Oncol 1997 15: 73–86
Winer EP, Gold D . Quality of life (QOL) following high dose chemotherapy with autologous bone marrow support (HDC) in patients with metastatic breast cancer Proc Am Soc Clin Oncol 1991 10: 62
Aisner JC, Cirrincione M, Perloff M . Combination chemotherapy for metastatic or recurrent carcinoma of the breast – a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study J Clin Oncol 1995 13: 1443–1452
Gluck S, Crump M, Bociek G, Stewart D . High dose chemotherapy with autologous blood stem cell transplantation: increasing evidence for efficacy in patients with metastatic breast cancer. Autologous Blood and Marrow Transplantation, Proc 9th Int Symp, Arlington, Texas 1999 pp 290–302
Lotz JP, Cure H, Morvan MJV et al. High dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: Results of the French Protocol PEGASE 04 Proc Am Soc Clin Oncol 1999 18: 161a
Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group New Engl J Med 2000 342: 1069–1076
Gluck S, Crump M . A randomized trial of high-dose chemotherapy and autologous stem cell therapy versus standard therapy in women with metastatic breast cancer who have responded to anthracycline or taxane-based induction chemotherapy National Cancer Institute of Canada Clinical Trials Group NCIC CTG Protocol Number MA 16 1997
Spiegel D, Bloom JR, Draemer HC, Gottheil E . Effect of psychosocial treatment on survival of patients with breast cancer Lancet 1989 ii: 888–891
Spiegel D . Essentials of psychotherapeutic intervention for cancer patients Supp Care Cancer 1995 3: 252–256
Spiegel D, Bloom JR, Yalom I . Group support for patients with metastatic cancer: a randomized prospective outcome study Arch Gen Psych 1981 38: 527–533
Bottomley A . Group cognitive behavioural therapy interventions with cancer patients: a review of the literature Eur J Cancer Care 1996 5: 143–146
Speca M, Carlson LE, Goodey E, Angen M . A randomized wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients Psychosom Med 2000 62: 613–622
Iacovino V, Reesor K . Literature on interventions to address cancer patients' psychosocial needs: what does it tell us? J Psych Oncol 1997 15: 47–71
Fobair P . Cancer support groups and group therapies: Part I. Historical and theoretical background and research on effectiveness J Psych Oncol 1997 15: 63–81
Acknowledgements
Dr Linda Carlson is a Research Fellow of the National Cancer Institute of Canada, supported with funds provided by the Canadian Cancer Society. We would like to acknowledge the assistance of Suzanne Cecchetto, Corolynn Sheehan, Sue Gerrard and Merle Heise for data management, and the contribution and dedication of the clinical staff at the Northeastern Ontario Regional Cancer Centre to the patient-related work.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carlson, L., Koski, T. & Glück, S. Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer. Bone Marrow Transplant 27, 989–998 (2001). https://doi.org/10.1038/sj.bmt.1703002
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703002
Keywords
This article is cited by
-
Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT
Bone Marrow Transplantation (2017)
-
Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance
Journal of Translational Medicine (2015)
-
Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007
Journal of Experimental & Clinical Cancer Research (2008)
-
Individualized exercise program for the treatment of severe fatigue in patients after allogeneic hematopoietic stem-cell transplant: a pilot study
Bone Marrow Transplantation (2006)
-
A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation
Bone Marrow Transplantation (2005)